Private-Label Drug Discounts and Best Price: Why a New Label Does Not Reset the Rebate

Private label Medicaid best price fraud occurs when a manufacturer knowingly leaves a qualifying private-label discount out of Best Price and underpays Medicaid rebates. The customer gets the cheaper drug. Medicaid gets a calculation that leaves that price out. If you work in contracting, product data or government pricing, the connection may be in front of you: a drug sold under a customer’s label, the agreement setting its price, and the decision to exclude that sale from Medicaid Best Price reporting.

Does a New Label Reset Medicaid Best Price?

A new label does not reset Medicaid Best Price. The Best Price rule requires a per-unit calculation without regard to package size, special packaging, labeling or identifiers on the drug or its package. Changing the name on the box leaves the underlying price question intact. That rule does not depend on whether the manufacturer or the customer applies the new label.

That rule reaches an operational detail familiar to product and contracting teams. The National Drug Code identifies the labeler, product and package. Those identifiers help connect the sale to the drug. The instruction to disregard special identifiers prevents the reporting calculation from treating the new label as a reason to drop a qualifying price.

The Medicaid definitions also include the business distributing a private-label product under its own label or trade name within the meaning of manufacturer. A review therefore follows both the product and the companies’ roles. Who made the drug, whose label appeared on it, who bought it and which price reached the government are parts of the same transaction.

What Counts Toward Best Price?

Best Price means the lowest qualifying price available from the manufacturer during the rebate quarter to a wholesaler, retailer, provider, HMO, nonprofit or governmental entity in the United States. The calculation captures price reductions that reach eligible purchasers directly or indirectly.

Cash and volume discounts, chargebacks, rebates and free goods contingent on a purchase can all lower that price. The invoice is only the starting point when another part of the agreement gives the customer more value. Later concessions also matter: the rule requires an adjustment when cumulative discounts or rebates subsequently change the price for the period.

The purchaser and the program matter alongside the discount. The rule expressly excludes specified Public Health Service and 340B prices, Federal Supply Schedule prices and prices negotiated for covered Medicare Part D drugs. A commercial HMO purchase must be evaluated on its own terms. The private label supplies no separate exclusion.

A contract can also condition a discount on buying another drug or meeting a performance requirement, such as formulary placement. That brings in the bundled-sale rule, which allocates discounts across the products in the arrangement. Private labeling asks whether the sale’s price was included. Bundling asks how the contract’s discount was allocated.

Why One Customer’s Discount Matters Beyond That Customer

A lower commercial price can affect the manufacturer’s obligations elsewhere. A 2018 Managed Care analysis, Indication-Specific Drug Pricing–Simple in Theory, Complex in Reality, describes that incentive in contracts that price a drug according to the condition it treats:

The article describes why a manufacturer cares about a discount beyond the customer receiving it. The private-label cases below show the alleged response: keep the HMO’s lower price out of the report to avoid the additional Medicaid rebate.

Aventis and the Private-Label Discounts

Aventis agreed to a $95.5 million settlement over alleged Best Price misreporting involving Azmacort, Nasacort and Nasacort AQ. The Justice Department’s May 28, 2009 announcement described private-label agreements with Kaiser Permanente that repackaged the manufacturer’s drugs under a new label. The settlement included over $6 million for certain Public Health Service entities that allegedly paid inflated prices.

The government alleged that Aventis used those agreements to avoid triggering a lower Best Price and the additional Medicaid rebates that would follow. The alleged misreporting covered 1995 through 2000. The commercial bargain gave the HMO a price the government said should have entered the rebate calculation. The label changed. According to the government, Medicaid lost the additional rebate.

The alleged harm reached beyond Medicaid. The Justice Department alleged that Aventis also overcharged those public health purchasers. One omitted price allegedly left Medicaid short on rebates and public health purchasers paying too much.

For a contracting employee, the important comparison is the agreement against the price report. For someone maintaining product data, it is the relationship between the manufacturer’s product and the private-label version. Those connections explain why this case turns on more than the name printed on the package.

Bayer Faced the Same Private-Label Allegation

A private label HMO discount omitted from Best Price was also the mechanism alleged against Bayer. The HHS and Justice Department report for fiscal 2003 describes discounted, relabeled sales of Cipro, an antibiotic, and Adalat, a blood-pressure drug, to a large HMO. The report calls this a “lick and stick scheme”: Bayer allegedly concealed the discounts and avoided paying Medicaid rebates.

The comparison with Aventis is direct. Different drugs went through the same commercial arrangement: discounted sales to an HMO under a different label, followed by an alleged failure to carry those prices into Medicaid’s calculation. The reporting question followed the price of the drug.

The same government report said GlaxoSmithKline agreed to pay more than $87 million in a civil settlement over repackaged Paxil and Flonase sold at deep discounts to the same HMO. The alleged consequence was again underpaid Medicaid rebates. Across these accounts, the useful pattern is the connection between the private-label contract and the omitted discount. That is the connection an insider’s records can make visible.

How Does an Omitted Discount Reduce the Medicaid Rebate?

Leaving out the lowest qualifying price makes reported Best Price too high, shrinking the difference between average manufacturer price and Best Price. When that difference determines the basic rebate, Medicaid receives less than it should.

Under the current Medicaid rebate calculation, the basic rebate per unit for most brand-name drugs is the greater of 23.1% of average manufacturer price or average manufacturer price minus Best Price. Average manufacturer price, commonly called AMP, and Best Price are different drug-pricing benchmarks. One supplies the average. The other supplies the qualifying low price against which it is compared.

This is the current formula. The private-label arrangements described above predate that minimum rate.

The Medicaid Drug Rebate Program applies the per-unit amount to the units paid for by the state. An additional inflation rebate can increase the total. The scale of the underpayment therefore depends on both the missing price concession and the Medicaid utilization to which the resulting rebate applies. A discount on a commercial sale can change what the manufacturer owes on Medicaid purchases of that drug.

How Does Best Price Affect the 340B Ceiling Price?

The 340B ceiling price uses the Medicaid unit rebate amount. Under the 340B ceiling-price rule, the manufacturer calculates the price quarterly for each covered outpatient drug by National Drug Code: the preceding quarter’s AMP for the smallest unit of measure, minus the unit rebate amount.

If an omitted Best Price discount makes the Medicaid unit rebate too small, that subtraction leaves a higher 340B ceiling price, holding AMP constant. The same reporting decision can therefore cut the rebate paid to Medicaid and raise the maximum price charged to a covered safety-net purchaser. That is the formula connection behind the Public Health Service overcharge consequence described in the Aventis case.

For an insider, the investigation follows the reported number into both destinations. The Medicaid rebate calculation shows the repayment effect. The 340B calculation and the covered purchaser’s price show the potential overcharge effect.

What Evidence Is Needed to Prove Fraud?

Private-label Best Price evidence connects the drug, the customer’s actual discount, the reported price and the decision that left the discount out. We work with contracting and pricing staff to trace that connection through the business records.

We compare the private-label agreement and product information with the invoices, credits, rebates and chargebacks that show the customer’s actual price. Then we trace that price into the calculation with you.

The reason for an exclusion matters as much as its result. A calculation assumption, an instruction about private-label sales or a response to an internal question can explain how the company arrived at the number. If someone challenged the treatment, we examine what they identified, who received the concern and how the company responded.

Manufacturers report quarterly AMP and Best Price to the Centers for Medicare & Medicaid Services, and a senior officer or delegate certifies the reports. The internal explanation for an exclusion can add something the reported number alone never reveals.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We connect the commercial records to the reporting decision and the public-program loss when assessing a private-label pricing case with you.

When You Know the Price Behind the Label

If you know which private-label discount disappeared from the rebate calculation, bring that discrepancy to our whistleblower experts. We work beside you to build your strongest Medicaid Best Price whistleblower case from the product, the bargain and the reporting decision, and bring in pharmaceutical whistleblower lawyers who understand Medicaid Best Price and 340B pricing.